EXPRESSION OF THE CELL-SURFACE ANTIGEN DETECTED BY THE MONOCLONAL ANTIBODY-A7 IN PANCREATIC-CARCINOMA CELL-LINES
EXPRESSION OF THE CELL-SURFACE ANTIGEN DETECTED BY THE MONOCLONAL ANTIBODY-A7 IN PANCREATIC-CARCINOMA CELL-LINES
复制标题
DOI：
10.1007/bf00308745
复制
发表时间：
1992-01-01
期刊：
影响因子：
--
通讯作者：
TAKAHASHI, T
中科院分区：
文献类型：
--
作者：
OTSUJI, E;YAMAGUCHI, T;TAKAHASHI, T
在以前的研究中，我们使用了鼠单克隆抗体，A7，对人结肠癌作为药物载体治疗结直肠癌。1在本研究中，我们发现，单克隆抗体A7也与73%的人胰腺癌细胞系发生化学反应，与A7抗原主要是在细胞表面检测。 然而，通过ELISA在这些人胰腺癌细胞系的用过的培养基中仅发现9%的A7抗原。 CA 19 -9、POA、铁蛋白、CEA、DU-PAN-2和SLX的阳性率分别为100%、64%、64%、55%、55%和36%。 这些结果表明，A7抗原可能只是很少脱落到胰腺癌患者的血清中，在这种情况下，MAb A7可能是胰腺癌患者的靶向化疗的合适的药物载体。
In a previous study, we used a murine monoclonal antibody, A7, against human colon carcinoma as a drug-carrier to treat colorectal cancer.1 In the present study, we found that MAb A7 also reacted immunohistochemically with 73% of human pancreatic carcinoma cell lines, with the A7 antigen mainly being detected on the cell surface. However, the A7 antigen was found in only 9% of the spent media of these human pancreatic carcinoma cell lines by ELISA. On the other hand, the positive incidence of CA19-9, POA, ferritin, CEA, DU-PAN-2 and SLX in those spent media was 100%, 64%, 64%, 55%, 55% and 36%, respectively. These results suggest that the A7 antigen may only rarely be shed into the sera of pancreatic cancer patients, in which case MAb A7 could be a suitable drug-carrier in targeting chemotherapy for pancreatic cancer patients.